PHOENIX (Geographic Atrophy) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an investigational drug called tinlarebant (the study drug) is safe and useful for treating geographic atrophy (GA).
What is the Condition Being Studied?
Geographic Atrophy (GA)
Who Can Participate in the Study?
Adults ages 60-85 who:
- Are diagnosed with geographic atrophy with lesions
- Do not have diabetic macular edema or another form of macular disease
- Have no inflammatory disease
For more information about who can be in this study, please contact the study team at DEC-RA@duke.edu.
Age Group
Adults
What is Involved?
If you choose to join the study, you will:
- Get a random assignment (like a coin flip) to take the study drug or a placebo (inactive substance)
- Keep in touch with the study team for about 2 years and 2 months
- Visit our clinic at the Duke Eye Center up to 11 times
At various visits, you will have blood tests, answer some questionnaires, and have eye exams and vision tests.
Study Details
Full Title
PHase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of Geographic Atrophy (the PHOENIX study) - LBS-008-CT05
Principal Investigator
Ophthalmologist
Protocol Number
IRB:
PRO00113726
NCT:
NCT05949593
Phase
Phase
III
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment